{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee JM"],"funding":["BLRD VA","Thoracic Surgery Foundation for Research and Education NIH NCI","NCATS NIH HHS","NHLBI NIH HHS","NCI NIH HHS","VA","NIH NCATS","CSRD VA","NIH NCI"],"pagination":["4556-4568"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5599263"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(16)"],"pubmed_abstract":["<b>Purpose:</b> A phase I study was conducted to determine safety, clinical efficacy, and antitumor immune responses in patients with advanced non-small cell lung carcinoma (NSCLC) following intratumoral administration of autologous dendritic cells (DC) transduced with an adenoviral (Ad) vector expressing the <i>CCL21</i> gene (Ad-CCL21-DC). We evaluated safety and tumor antigen-specific immune responses following <i>in situ</i> vaccination (ClinicalTrials.gov: NCT01574222).<b>Experimental Design:</b> Sixteen stage IIIB/IV NSCLC subjects received two vaccinations (1 × 10<sup>6</sup>, 5 × 10<sup>6</sup>, 1 × 10<sup>7</sup>, or 3 × 10<sup>7</sup> DCs/injection) by CT- or bronchoscopic-guided intratumoral injections (days 0 and 7). Immune responses were assessed by tumor antigen-specific peri"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Phase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8<sup>+</sup> T-cell Infiltration."],"pmcid":["PMC5599263"],"funding_grant_id":["U01 CA196408","1I01CX000345-01","NCIK23 CA131577","U01 CA214182","UL1 TR001881","NCIR21 CA105705","I01 BX000359","P50 CA090388","T32 CA009120","R01 CA085686","UL1-TR001881","T32 HL072752","NCI5 K12 CA076905","R01 CA208403","I01 CX000345","NCIL30 CA142223","R21 CA105705"],"pubmed_authors":["Lee S","Walser TC","Wang G","Lin Y","Marincola FM","Schaue D","Lee G","Suh R","Goldman JW","Dubinett SM","Lee JM","Salehi-Rad R","Park SJ","Abtin F","Wallace WD","Lee MH","Sharma S","Garon E","Rosen F","Yanagawa J","Elashoff DA","Adams S","Reckamp KL","Baratelli FE","Zeng G","Tumeh PC"],"additional_accession":[]},"is_claimable":false,"name":"Phase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8<sup>+</sup> T-cell Infiltration.","description":"<b>Purpose:</b> A phase I study was conducted to determine safety, clinical efficacy, and antitumor immune responses in patients with advanced non-small cell lung carcinoma (NSCLC) following intratumoral administration of autologous dendritic cells (DC) transduced with an adenoviral (Ad) vector expressing the <i>CCL21</i> gene (Ad-CCL21-DC). We evaluated safety and tumor antigen-specific immune responses following <i>in situ</i> vaccination (ClinicalTrials.gov: NCT01574222).<b>Experimental Design:</b> Sixteen stage IIIB/IV NSCLC subjects received two vaccinations (1 × 10<sup>6</sup>, 5 × 10<sup>6</sup>, 1 × 10<sup>7</sup>, or 3 × 10<sup>7</sup> DCs/injection) by CT- or bronchoscopic-guided intratumoral injections (days 0 and 7). Immune responses were assessed by tumor antigen-specific peri","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Aug","modification":"2026-05-04T17:14:50.243Z","creation":"2019-03-26T23:51:08Z"},"accession":"S-EPMC5599263","cross_references":{"pubmed":["28468947"],"doi":["10.1158/1078-0432.CCR-16-2821","10.1158/1078-0432.ccr-16-2821"]}}